Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
September 10 2017 - 11:45AM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, announced that an
oral poster discussion featuring data related to FPA150, Five
Prime’s novel B7-H4 antibody, was presented today at the European
Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
The poster titled “FPA150, a Novel B7-H4 Therapeutic Antibody with
Checkpoint Blockade and ADCC Activities” by Charles Kaplan et al.
is available at
http://www.fiveprime.com/news-media/publications-presentations.
“B7-H4 represents an ideal target for a therapeutic antibody,”
said Bryan Irving, Ph.D., Senior Vice President of Research at Five
Prime. “B7-H4 is expressed in several solid tumor types not
typically associated with PD-L1 expression and its expression
negatively correlates with patient outcome. Moreover, B7-H4
represents a T cell checkpoint ligand that is not currently
targeted by other immuno-oncology agents. As such, we feel that our
monoclonal B7-H4 antibody, FPA150, which appears to possess both T
cell checkpoint blockade activity and enhanced ADCC, has the
potential to be an effective therapeutic by improving anti-tumor
immune responses in cancer patients who may not respond well to
PD-1 or PD-L1-targeted agents.”
B7-H4 shares significant homology with other B7 family members,
including PD-L1 and PD-L2. B7-H4 is expressed in several human
tumors such as carcinomas of the breast, ovary and endometrium, and
its expression tends to correlate with poor prognosis. While the
receptor for B7-H4 is unknown, it is believed to be expressed on T
cells because B7-H4 is described as a ligand capable of directly
inhibiting T cell activity.
FPA150 is a high affinity, afucosylated B7-H4 monoclonal
antibody that has demonstrated potent antibody-dependent
cell-mediated cytotoxicity (ADCC) and T cell checkpoint blockade
activity in vitro and significant dose-dependent anti-tumor
efficacy in vivo.
Five Prime is currently developing FPA150 and IND-enabling
studies are ongoing.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious
diseases. Five Prime's comprehensive discovery platform, which
encompasses virtually every medically relevant extracellular
protein, positions it to explore pathways in cancer, inflammation
and their intersection in immuno-oncology, an area with significant
therapeutic potential and a growing focus of the company's R&D
activities. Five Prime has entered into strategic collaborations
with leading global pharmaceutical companies and has promising
product candidates in clinical and late preclinical development.
For more information, please visit www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime's
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
CONTACT:Derek
Cole720-785-4497derek.cole@iradvisory.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024